General Information of Drug Combination (ID: DC7IB28)

Drug Combination Name
SY-1425 Vinflunine
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs SY-1425   DMH8UF0 Vinflunine   DMTJAEP
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: OVCAR3
Zero Interaction Potency (ZIP) Score: 10.82
Bliss Independence Score: 12.05
Loewe Additivity Score: 11.28
LHighest Single Agent (HSA) Score: 9.5

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of SY-1425
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 1 [2]
Myelodysplastic syndrome 2A37 Phase 1 [2]
SY-1425 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Retinoic acid receptor alpha (RARA) TTW38KT RARA_HUMAN Agonist [2]
------------------------------------------------------------------------------------
Indication(s) of Vinflunine
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [3]

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult acute myeloid leukemia DCMXQGT HL-60(TB) Investigative [4]
Adult T acute lymphoblastic leukemia DCNMWLG MOLT-4 Investigative [4]
Astrocytoma DC0ZOL9 U251 Investigative [4]
Astrocytoma DC475S3 SNB-19 Investigative [4]
Childhood T acute lymphoblastic leukemia DCA69Z7 CCRF-CEM Investigative [4]
Chronic myelogenous leukemia DCIM8MA K-562 Investigative [4]
Glioblastoma DCKH99K SNB-75 Investigative [4]
Plasma cell myeloma DCSXPKQ RPMI-8226 Investigative [4]
Renal cell carcinoma DCZ4DXJ SN12C Investigative [4]
Carcinoma DC8N5UQ MCF7 Investigative [5]
Colon carcinoma DCGHHUF KM12 Investigative [5]
Invasive ductal carcinoma DCWKSPV BT-549 Investigative [5]
Adenocarcinoma DC5X5PH HT29 Investigative [1]
Cutaneous melanoma DCGHP7R SK-MEL-5 Investigative [1]
High grade ovarian serous adenocarcinoma DCUJYGX OVCAR-8 Investigative [1]
Lung adenocarcinoma DC934VJ HOP-62 Investigative [1]
Malignant melanoma DC5FO64 LOX IMVI Investigative [1]
Malignant melanoma DCED3UH UACC62 Investigative [1]
Non-small cell lung carcinoma DCVQRWN HOP-92 Investigative [1]
Pleural epithelioid mesothelioma DCE77KE NCI-H226 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 20 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.